The flurry of recent de-SPAC transactions has several implications for other companies, particularly companies with investments in those entities, including ongoing reporting obligations, impacts on the financial reporting process, policies, and procedures relating to designated board representatives and trading restrictions. Each of these issues is explored in more depth in this article. For public companies impacted by one or more of these matters, leveraging aspects of existing compliance programs and including cross-functional teams in those processes early on can prove beneficial.
*Reprinted from Insights: The Corporate and Securities Law Advisor, Volume 36, Number 3 (March 2022), pp. 17-19, with permission of Kluwer Law International.
